JNJ - Performance Comparison: Johnson & Johnson And Competitors In Pharmaceuticals Industry | Benzinga
In the fast-paced and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating Johnson & Johnson (NYSE:JNJ) in comparison to its major competitors within the Pharmaceuticals industry. By analyzing crucial financial metrics, market position, and growth potential, our objective is to provide valuable insights for investors and offer a deeper understanding of company's performance in the industry.
Johnson & Johnson Background
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
| Company | P/E | P/B | P/S | ROE | EBITDA (in billions) | Gross Profit (in billions) | Revenue Growth |
|---|---|---|---|---|---|---|---|
| Johnson & Johnson | |||||||
| 21.79 | |||||||
| 5.04 | |||||||
| 4.31 | |||||||
| 4.69% | |||||||
| $5.68 | |||||||
| $14.87 | |||||||
| 2.34% | |||||||
| Eli Lilly and Co | |||||||
| 120.82 | |||||||
| 60.85 | |||||||
| 20.63 | |||||||
| 19.02% | |||||||
| $3.12 | |||||||
| $7.09 | |||||||
| 25.98% | |||||||
| Novo Nordisk A/S | |||||||
| 46.93 | |||||||
| 42.08 | |||||||
| 17.15 | |||||||
| 24.73% | |||||||
| $36.91 | |||||||
| $55.43 | |||||||
| 22.45% | |||||||
| Merck & Co Inc | |||||||
| 139.49 | |||||||
| 7.88 | |||||||
| 5.20 | |||||||
| 12.22% | |||||||
| $6.96 | |||||||
| $12.23 | |||||||
| 8.89% | |||||||
| AstraZeneca PLC | |||||||
| 38.53 | |||||||
| 6.46 | |||||||
| 5.12 | |||||||
| 5.69% | |||||||
| $4.47 | |||||||
| $10.46 | |||||||
| 16.55% | |||||||
| Novartis AG | |||||||
| 23.44 | |||||||
| 5.30 | |||||||
| 4.49 | |||||||
| 6.23% | |||||||
| $4.66 | |||||||
| $9.02 | |||||||
| 9.71% | |||||||
| GSK PLC | |||||||
| 16.20 | |||||||
| 5.19 | |||||||
| 2.36 | |||||||
| 2.64% | |||||||
| $2.07 | |||||||
| $5.39 | |||||||
| 9.16% | |||||||
| Zoetis Inc | |||||||
| 32.67 | |||||||
| 15.30 | |||||||
| 8.95 | |||||||
| 11.91% | |||||||
| $0.93 | |||||||
| $1.55 | |||||||
| 9.5% | |||||||
| Takeda Pharmaceutical Co Ltd | |||||||
| 46.16 | |||||||
| 0.91 | |||||||
| 1.56 | |||||||
| -0.04% | |||||||
| $186.41 | |||||||
| $668.37 | |||||||
| -5.43% | |||||||
| Dr Reddy's Laboratories Ltd | |||||||
| 17.11 | |||||||
| 3.37 | |||||||
| 3.42 | |||||||
| 4.76% | |||||||
| $20.32 | |||||||
| $49.91 | |||||||
| -1.83% | |||||||
| Jazz Pharmaceuticals PLC | |||||||
| 21.79 | |||||||
| 1.79 | |||||||
| 1.90 | |||||||
| -0.39% | |||||||
| $0.23 | |||||||
| $0.81 | |||||||
| 1.03% | |||||||
| Prestige Consumer Healthcare Inc | |||||||
| 15.42 | |||||||
| 1.94 | |||||||
| 2.87 | |||||||
| 3.04% | |||||||
| $0.09 | |||||||
| $0.15 | |||||||
| -3.11% | |||||||
| Corcept Therapeutics Inc | |||||||
| 28.73 | |||||||
| 5.73 | |||||||
| 6.36 | |||||||
| 5.22% | |||||||
| $0.03 | |||||||
| $0.14 | |||||||
| 38.95% | |||||||
| Indivior PLC | |||||||
| 458 | |||||||
| 246.88 | |||||||
| 2.30 | |||||||
| 940.0% | |||||||
| $0.08 | |||||||
| $0.24 | |||||||
| 12.25% | |||||||
| Average | |||||||
| 77.33 | |||||||
| 31.05 | |||||||
| 6.33 | |||||||
| 79.62% | |||||||
| $20.48 | |||||||
| $63.14 | |||||||
| 11.08% |